DrugPatentWatch Database Preview
BEPREVE Drug Profile
see a sample report or, see our see our flat-rate plans
When do Bepreve patents expire, and when can generic versions of Bepreve launch?
This drug has forty-five patent family members in sixteen countries.
The generic ingredient in BEPREVE is bepotastine besilate. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the bepotastine besilate profile page.
Summary for BEPREVE
| International Patents: | 45 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 58 |
| Clinical Trials: | 5 |
| Patent Applications: | 15 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for BEPREVE |
| DailyMed Link: | BEPREVE at DailyMed |
Generic Entry Opportunity Date for BEPREVE
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for BEPREVE
| Drug Class | Histamine-1 Receptor Antagonist |
Synonyms for BEPREVE
| (+)-(S)-4-(4-((4-Chlorophenyl)(2-pyridyl)methoxy)piperidino)butyric acid monobenzenesulfonate |
| (+)-(S)-4-[4-[1-(4-Chlorophenyl)-1-(2-pyridyl)methoxy]piperidin-1-yl]butyric acid benzenesulfonate |
| (S)-4-(4-((4-chlorophenyl)(pyridin-2-yl)methoxy)piperidin-1-yl)butanoic acid compound with benzenesulfonic acid (1:1) |
| (S)-4-[4-(4-Chlorophenyl-2-pyridylmethoxy)piperidinyl]butyric Acid Benzenesulfonate |
| (s)-4-[4-[(4-chlorophenyl)(2-pyridyl)-methoxy]piperidino]butanoic acid monobenzenesulfonic acid salt |
| (s)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butanoic acid monobenzenesulfonic acid salt |
| 1-Piperidinebutanoic acid, 4-((4-chlorophenyl)-2-pyridinylmethoxy)- (S)-, monobenzenesulfonate |
| 1-piperidinebutanoic acid, 4-[(4-chlorophenyl)-2-pyridinylmethoxy]-, (s)-, monobenzenesulfonate |
| 1-piperidinebutanoic acid, 4-[(s)-(4-chlorophenyl)-2-pyridinylmethoxy]-, monobenzenesulfonate |
| 190786-44-8 |
| 4-((4-Chlorophenyl)-2-pyridinylmethoxy)- (S)-1-piperidinebutanoic acid monobenzenesulfonate |
| 4-[(S)-(4-Chlorophenyl)-2-pyridinylmethoxy]-1-piperidinebutanoic Acid Benzenesulfonate |
| 4-[4-[(r)-(4-chlorophenyl)-pyridin-2-yl-methoxy]-1-piperidyl]butanoic acid |
| 4-{4-[(s)-(4-chlorophenyl)(pyridin-2-yl)methoxy]piperidin-1-yl}butanoic acid benzenesulfonate |
| 6W18MO1QR3 |
| 786B448 |
| ABP001064 |
| AC-24015 |
| AC1L4UXJ |
| AC1Q6WSY |
| AK322015 |
| AKOS025401655 |
| AN-5247 |
| API0001668 |
| AS-17863 |
| BC214879 |
| benzenesulfonic acid; 4-[4-[(S)-(4-chlorophenyl)-(2-pyridyl)methoxy]-1-piperidyl]butanoic acid |
| benzenesulfonic acid; 4-[4-[(S)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid |
| benzenesulfonic acid;4-[4-[(S)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid |
| Bepomax |
| Bepotastine (Beslilate) |
| Bepotastine benzenesulfonate |
| Bepotastine Benzenesulfonate Salt |
| Bepotastine besilate |
| Bepotastine besilate (JP17) |
| Bepotastine Besitate |
| Bepotastine Beslilat |
| Bepotastine besylate |
| Bepotastine besylate (USAN) |
| Bepotastine besylate [USAN] |
| Bepreve (TN) |
| Betotastine besilate |
| C27H31ClN2O6S |
| CB0259 |
| CHEBI:31281 |
| CHEMBL1201759 |
| CS-0383 |
| CTK4E0497 |
| D01654 |
| DTXSID80172577 |
| FT-0655883 |
| HY-A0015 |
| J-012325 |
| KS-00000FR0 |
| LS-114358 |
| MFCD01938491 |
| MolPort-005-938-034 |
| PubChem19122 |
| s3037 |
| SC-47417 |
| SCHEMBL1287638 |
| Talion |
| Talion (TN) |
| TAU-284 |
| tau284 |
| UDGHXQPQKQPSBB-BOXHHOBZSA-N |
| UNII-6W18MO1QR3 |
| V2224 |
| W-5279 |
US Patents and Regulatory Information for BEPREVE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb Inc | BEPREVE | bepotastine besilate | SOLUTION/DROPS;OPHTHALMIC | 022288-001 | Sep 8, 2009 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Bausch And Lomb Inc | BEPREVE | bepotastine besilate | SOLUTION/DROPS;OPHTHALMIC | 022288-001 | Sep 8, 2009 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Bausch And Lomb Inc | BEPREVE | bepotastine besilate | SOLUTION/DROPS;OPHTHALMIC | 022288-001 | Sep 8, 2009 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Paragraph IV (Patent) Challenges for BEPREVE
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Ophthalmic Solution | 1.5% | ➤ Subscribe | ➤ Sign Up |
Non-Orange Book US Patents for BEPREVE
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 6,307,052 | Acid-addition salts of optically active piperidine compound and process for producing the same | ➤ Sign Up |
| 8,883,825 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations | ➤ Sign Up |
| 9,849,121 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations | ➤ Sign Up |
| 7,282,589 | Acid addition salt of optically active piperidine compound and process for preparing the same | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
see a sample report or, see our see our flat-rate plans
